Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 8:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 992 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Comparison control condition Clear all
Active, not recruiting Not applicable Interventional

Durham Connects RCT Evaluation

NCT01406184
View directory record Official record
Conditions
Unspecified Child Maltreatment, Suspected, Unspecified Child Maltreatment, Confirmed
Interventions
Durham Connects
Other
Lead sponsor
Duke University
Other
Eligibility
Up to 6 Months
Enrollment
2,329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 30, 2026, 8:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of the CHIME Intervention for Improving Early Head Start/Head Start Educator Well-being

NCT05791825
View directory record Official record
Conditions
Health, Subjective, Work Related Stress, Compassion, Social Skills
Interventions
Cultivating Healthy Intentional Mindful Educators
Behavioral
Lead sponsor
University of Nebraska Lincoln
Other
Eligibility
Not listed
Enrollment
571 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 30, 2026, 8:24 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Comparison of ALD, NASH, and Healthy Control Patients

NCT03224949
View directory record Official record
Conditions
ALD - Alcoholic Liver Disease
Interventions
Blood draw
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 30, 2026, 8:24 PM EDT
Terminated Phase 1 Interventional Results available

Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis

NCT03594487
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
FMP30 Donor Stool, Fecal Microbiota Transplantation (FMT) of FMP30 Donor Stool, Observational Control
Drug · Procedure · Other
Lead sponsor
Jeffrey Gelfand
Other
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 30, 2026, 8:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effectiveness of Trauma Management Therapy and Prolonged Exposure Therapy

NCT04549493
View directory record Official record
Conditions
PTSD
Interventions
Exposure Therapy
Behavioral
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years to 64 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Oct 30, 2026, 8:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Speed of Processing Training in Patients With Parkinson's Disease and Healthy Older Adults

NCT02929758
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Speed of processing training (SOPT)
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
50 Years and older
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 26, 2018 · Synced Oct 30, 2026, 8:24 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Cognitive and Electrophysiological Assessment of Non-Invasive Temporally-Interfering Electric Fields Stimulation (TIEFS)

NCT07663578
View directory record Official record
Conditions
Epilepsy
Interventions
Temporal Interference Electrical Stimulation
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 30, 2026, 8:24 PM EDT
Completed Phase 2 Interventional

Incentive-based Smoking Cessation for Methadone Patients

NCT00718835
View directory record Official record
Conditions
Cigarette Smoking Among Patients Currently Receiving Methadone or Buprenorphine Treatment for Opioid Dependence
Interventions
incentive-based contingency management
Behavioral
Lead sponsor
University of Vermont Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 21, 2014 · Synced Oct 30, 2026, 8:24 PM EDT
Completed Phase 2 Interventional

A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDS

NCT00001058
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Ethambutol hydrochloride, Clarithromycin, Rifabutin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
33
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 30, 2026, 8:24 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Alcohol Dependency in Patients With Bipolar Disorder

NCT00114686
View directory record Official record
Conditions
Bipolar I Disorder, Alcohol Dependence
Interventions
Quetiapine fumarate, lithium, divalproex
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
21 Years to 60 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
38
States / cities
Cerritos, California • San Diego, California • New Haven, Connecticut + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2013 · Synced Oct 30, 2026, 8:24 PM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Metformin Compared to Insulin in Pregnant Women With Mild Preexisting or Early Gestational Diabetes

NCT00835861
View directory record Official record
Conditions
Non Insulin Dependent Diabetes, Pregnancy
Interventions
Metformin, Insulin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 30, 2026, 8:24 PM EDT
Completed Not applicable Interventional Results available

Uric Acid and the Endothelium in CKD

NCT01228903
View directory record Official record
Conditions
Kidney Disease
Interventions
Allopurinol, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 30, 2026, 8:24 PM EDT
Terminated Phase 3 Interventional Results available

A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Nondialysis-Dependent Chronic Kidney Disease

NCT01155388
View directory record Official record
Conditions
Iron Deficiency Anemia, Nondialysis-dependent Chronic Kidney Disease
Interventions
Ferumoxytol, Oral Iron
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
6 Months to 17 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Oct 30, 2026, 8:24 PM EDT
Completed Not applicable Interventional

Home Parenteral Nutrition (HPN) Families' Mobile Distance Connections to Care Research

NCT01900288
View directory record Official record
Conditions
Short Bowel Syndrome, Malabsorption, Malnutrition
Interventions
HPN Group Clinic Appointments using Mobile Devices (experimental), Mobile Device Access (placebo)
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
13 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2017 · Synced Oct 30, 2026, 8:24 PM EDT
Completed Phase 2 Interventional Results available

To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies

NCT01068860
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Interventions
Canakinumab 150 mg, Placebo to Canakinumab
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 74 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
11
States / cities
Los Angeles, California • Santa Ana, California • Spring Valley, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2011 · Synced Oct 30, 2026, 8:24 PM EDT
Completed Phase 3 Interventional Results available

A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)

NCT03125902
View directory record Official record
Conditions
Triple-Negative Breast Cancer
Interventions
Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody, Atezolizumab Placebo, Paclitaxel
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
8
States / cities
Stanford, California • Fort Myers, Florida • St. Petersburg, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 30, 2026, 8:24 PM EDT
Completed Not applicable Interventional Results available

Thriving in the Midst of Moral Pain: The Acceptability and Feasibility of Acceptance and Commitment Therapy for Moral Injury (ACT-MI) Among Warzone Veterans

NCT03760731
View directory record Official record
Conditions
Moral Injury
Interventions
Acceptance and Commitment Therapy for Moral Injury (ACT-MI), Present Centered Therapy for Moral Injury (PCT-MI)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 89 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Oct 30, 2026, 8:24 PM EDT
Terminated Phase 3 Interventional Results available

A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma

NCT02715804
View directory record Official record
Conditions
Pancreatic Ductal Carcinoma
Interventions
Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20), Placebo, nab-Paclitaxel, Gemcitabine
Other · Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
492 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
64
States / cities
Mobile, Alabama • Gilbert, Arizona • Fayetteville, Arkansas + 52 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 30, 2026, 8:24 PM EDT
Active, not recruiting Phase 3 Interventional

Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations

NCT04006210
View directory record Official record
Conditions
Parkinson's Disease
Interventions
ND0612 Solution for SC infusion, Placebo for SC infusion, Oral IR-LD/CD, Placebo for Oral IR-LD/CD
Combination Product · Drug
Lead sponsor
NeuroDerm Ltd.
Industry
Eligibility
30 Years and older
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
38
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 30, 2026, 8:24 PM EDT
Completed Phase 2 Interventional Results available

ICON-2: FMT and Bezlotoxumab Compared to FMT and Placebo for Patients With IBD and CDI

NCT03829475
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Clostridium Difficile Infection
Interventions
Bezlotoxumab, Placebo, Fecal Microbiota Transplantation
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 30, 2026, 8:24 PM EDT
Completed Phase 3 Interventional Results available

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

NCT01777152
View directory record Official record
Conditions
Anaplastic Large-Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell Lymphoma
Interventions
brentuximab vedotin, doxorubicin, prednisone, vincristine, cyclophosphamide
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
32
States / cities
Gilbert, Arizona • Duarte, California • Stanford, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Oct 30, 2026, 8:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Online Expert Peer Facilitation of the EVERYbody Project

NCT05336253
View directory record Official record
Conditions
Body Image, Eating Disorder Symptom, Weight Bias
Interventions
EVERYbody Project-Connect, Self-Help Workbook
Behavioral
Lead sponsor
Western Washington University
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Bellingham, Washington
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Oct 30, 2026, 8:24 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations

NCT03670953
View directory record Official record
Conditions
Parkinson's Disease (Disorder)
Interventions
IR CD-LD, IPX203 ER CD-LD, Placebo Matching IPX203, Placebo Matching IR CD-LD
Drug · Other
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
40 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
56
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 46 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 30, 2026, 8:24 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Healthy Adolescent Transitions (HAT)

NCT03194672
View directory record Official record
Conditions
Pregnancy Prevention, Life Skill Development
Interventions
Healthy Adolescent Transitions (HAT) program
Behavioral
Lead sponsor
Jack Stevens
Other
Eligibility
14 Years to 19 Years · Female only
Enrollment
331 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Oct 30, 2026, 8:24 PM EDT